TCGA-CV-A45T-01A-11R-A24H-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.108675799
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.560
- INFLAMMATORY_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- MYOGENESIS+0.350
- COMPLEMENT+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- KRAS_SIGNALING_UP+0.250
- IL2_STAT5_SIGNALING+0.220
Top 10 suppressed
- MITOTIC_SPINDLE-0.470
- HEDGEHOG_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.370
- PROTEIN_SECRETION-0.350
- G2M_CHECKPOINT-0.330
- UV_RESPONSE_DN-0.330
- ANGIOGENESIS-0.260
- ESTROGEN_RESPONSE_EARLY-0.240
- HYPOXIA-0.240
- ANDROGEN_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.882 |
| 2 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.871 |
| 3 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.838 |
| 4 | TCGA-E2-A14Z-01A-11R-A115-07 | — | D | 0.829 |
| 5 | SRR2016951 | — | — | 0.826 |
| 6 | 0ec02d90-7ccb-476e-a8bb-9a9c8f158dee | — | — | 0.825 |
| 7 | TCGA-LL-A5YO-01A-21R-A28M-07 | — | D | 0.818 |
| 8 | TCGA-BH-A2L8-01A-11R-A18M-07 | — | A | 0.818 |
| 9 | TCGA-CQ-5333-01A-01R-2403-07 | — | — | 0.818 |
| 10 | MNG718 | — | — | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |